Full text is available at the source.
Lancet (London, England)···
Weekly tirzepatide compared to daily insulin as add-on treatments for type 2 diabetes with metformin, with or without SGLT2 inhibitors
Updated
Abstract
From a mean baseline HbA of 8.17%, tirzepatide reduced HbA by 1.93% to 2.37% at week 52, while insulin degludec reduced it by 1.34%.
- Tirzepatide doses of 5 mg, 10 mg, and 15 mg showed significant reductions in HbA compared to insulin degludec, with estimated treatment differences of -0.59% to -1.04%.
- The proportion of participants achieving a HbA of less than 7.0% was significantly higher in the tirzepatide groups (82%-93%) compared to insulin degludec (61%).
- All tirzepatide doses resulted in bodyweight reductions ranging from -7.5 kg to -12.9 kg, while insulin degludec was associated with a weight increase of 2.3 kg.
- Mild to moderate gastrointestinal events were the most common adverse effects among tirzepatide-treated participants, with nausea occurring in 12-24% of cases.
- Participants on tirzepatide had a lower incidence of hypoglycaemia compared to those treated with insulin degludec (1-2% vs. 7%).
Simplified
BACKGROUND: Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist under development for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of tirzepatide versus titrated insulin degludec in people with type 2 diabetes inadequately controlled by metformin with or without SGLT2 inhibitors.
METHODS: In this open-label, parallel-group, multicentre (122 sites), multinational (13 countries), phase 3 study, eligible participants (aged ≥18 years) had a baseline glycated haemoglobin (HbA) of 7·0-10·5%, body-mass index of at least 25 kg/m, stable weight, and were insulin-naive and treated with metformin alone or in combination with an SGLT2 inhibitor for at least 3 months before screening. Participants were randomly assigned (1:1:1:1), using an interactive web-response system, to once-weekly subcutaneous injection of tirzepatide (5, 10, or 15 mg) or once-daily subcutaneous injection of titrated insulin degludec, and were stratified by country, HbA, and concomitant use of oral antihyperglycaemic medications. Tirzepatide was initially given at 2·5 mg and the dose was escalated by 2·5 mg every 4 weeks until the assigned dose was reached. Insulin degludec was initially given at 10 U per day and was titrated once weekly to a fasting self-monitored blood glucose of less than 5·0 mmol/L (<90 mg/dL), following a treat-to-target algorithm, for 52 weeks. The primary efficacy endpoint was non-inferiority of tirzepatide 10 mg or 15 mg, or both, versus insulin degludec in mean change from baseline in HbAat week 52. Key secondary efficacy endpoints were non-inferiority of tirzepatide 5 mg versus insulin degludec in mean change from baseline in HbAat week 52, superiority of all doses of tirzepatide versus insulin degludec in mean change from baseline in HbAand bodyweight, and the proportion of participants achieving HbAof less than 7·0% (<53 mmol/mol) at week 52. We used a boundary of 0·3% to establish non-inferiority in HbAdifference between treatments. Efficacy and safety analyses were assessed in the modified intention-to-treat population (all participants who received at least one dose of study drug). This trial is registered with ClinicalTrials.gov, number NCT03882970, and is complete. 1c1c1c1c1c1c1c2
FINDINGS: Between April 1 and Nov 15, 2019, we assessed 1947 participants for eligibility, 1444 of whom were randomly assigned to treatment. The modified intention-to-treat population was 1437 participants from the tirzepatide 5 mg (n=358), tirzepatide 10 mg (n=360), tirzepatide 15 mg (n=359), and insulin degludec (n=360) groups. From a mean baseline HbAof 8·17% (SD 0·91), the reductions in HbAat week 52 were 1·93% (SE 0·05) for tirzepatide 5 mg, 2·20% (0·05) for tirzepatide 10 mg, and 2·37% (0·05) for tirzepatide 15 mg, and 1·34% (0·05) for insulin degludec. The non-inferiority margin of 0·3% was met. The estimated treatment difference (ETD) versus insulin degludec ranged from -0·59% to -1·04% for tirzepatide (p<0·0001 for all tirzepatide doses). The proportion of participants achieving a HbAof less than 7·0% (<53 mmol/mol) at week 52 was greater (p<0·0001) in all three tirzepatide groups (82%-93%) versus insulin degludec (61%). At week 52, from a baseline of 94·3 kg (SD 20·1), all three tirzepatide doses decreased bodyweight (-7·5 kg to -12·9 kg), whereas insulin degludec increased bodyweight by 2·3 kg. The ETD versus insulin degludec ranged from -9·8 kg to -15·2 kg for tirzepatide (p<0·0001 for all tirzepatide doses). The most common adverse events in tirzepatide-treated participants were mild to moderate gastrointestinal events that decreased over time. A higher incidence of nausea (12-24%), diarrhoea (15-17%), decreased appetite (6-12%), and vomiting (6-10%) was reported in participants treated with tirzepatide than in those treated with insulin degludec (2%, 4%, 1%, and 1%, respectively). Hypoglycaemia (<54 mg/dL or severe) was reported in five (1%), four (1%), and eight (2%) participants on tirzepatide 5, 10, and 15 mg, respectively, versus 26 (7%) on insulin degludec. Treatment discontinuation due to an adverse event was more common in the tirzepatide groups than in the insulin degludec group. Five participants died during the study; none of the deaths were considered by the investigators to be related to the study treatment. 1c1c1c
INTERPRETATION: In patients with type 2 diabetes, tirzepatide (5, 10, and 15 mg) was superior to titrated insulin degludec, with greater reductions in HbAand bodyweight at week 52 and a lower risk of hypoglycaemia. Tirzepatide showed a similar safety profile to that of GLP-1 receptor agonists. 1c
FUNDING: Eli Lilly and Company.
Related papers
Apr '22
Weekly tirzepatide compared to daily insulin degludec for blood sugar control in adults with type 2 diabetes measured by continuous glucose monitoring
top 1% journal
cited by 51 papers
randomized controlled trial
Apr '22
Tirzepatide versus insulin degludec effects on liver fat and belly fat in people with type 2 diabetes
top 1% journal
cited by 417 papers
randomized controlled trial
Oct '21
Tirzepatide compared to insulin glargine in type 2 diabetes patients with higher heart risk
top 1% journal
cited by 544 papers
clinical trial, phase iii
Mar '17
Effectiveness and safety of weekly semaglutide compared to daily insulin glargine added to metformin in people with type 2 diabetes who have not used insulin
top 1% journal
cited by 393 papers
randomized controlled trial
Jun '21
Effectiveness and safety of tirzepatide, a new drug activating two blood sugar control systems, in people with type 2 diabetes
top 1% journal
cited by 876 papers
randomized controlled trial
Oct '18
Safety and effectiveness of LY3298176, a new drug targeting two hormone receptors, in people with type 2 diabetes: a controlled phase 2 trial
top 1% journal
cited by 714 papers
randomized controlled trial
Feb '23
Safety and effectiveness of once-weekly long-lasting insulin in people with type 2 diabetes already using daily insulin
top 1% journal
cited by 50 papers
randomized controlled trial
Aug '22
Safety and effectiveness of tirzepatide added to one oral diabetes medicine in Japanese patients with type 2 diabetes
top 1% journal
cited by 111 papers
randomized controlled trial
Apr '22
Tirzepatide compared to placebo or semaglutide on insulin production and sensitivity in adults with type 2 diabetes
top 1% journal
cited by 219 papers
randomized controlled trial
Apr '17
Weekly semaglutide compared to daily sitagliptin added to diabetes pills in type 2 diabetes over 56 weeks: a safety and effectiveness trial
top 1% journal
cited by 420 papers
randomized controlled trial